RAMM Pharma Corp.
RAMM
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -13.61% | -2.75% | 6.74% | 24.39% | 28.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -13.61% | -2.75% | 6.74% | 24.39% | 28.71% |
| Cost of Revenue | -0.22% | 15.04% | 21.61% | 31.32% | -2.21% |
| Gross Profit | -58.05% | -74.04% | -64.20% | -23.83% | 2,676.32% |
| SG&A Expenses | -16.56% | -12.73% | -18.55% | -15.03% | 16.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -280.00% | -214.29% | -76.92% | 100.00% |
| Total Operating Expenses | -11.60% | -4.17% | -6.74% | -1.67% | 9.93% |
| Operating Income | 10.24% | 5.07% | 14.22% | 14.50% | -0.01% |
| Income Before Tax | 57.12% | 57.08% | 60.49% | 64.13% | -192.05% |
| Income Tax Expenses | 12.70% | 12.70% | 12.70% | 12.70% | 43.18% |
| Earnings from Continuing Operations | 57.09% | 57.05% | 60.46% | 64.10% | -191.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.09% | 57.05% | 60.46% | 64.10% | -191.92% |
| EBIT | 10.24% | 5.07% | 14.22% | 14.50% | -0.01% |
| EBITDA | 4.93% | 0.18% | 16.70% | 20.51% | 7.78% |
| EPS Basic | 56.05% | 56.02% | 59.56% | 63.41% | -194.10% |
| Normalized Basic EPS | -14.02% | -12.64% | 1.06% | 14.48% | 0.38% |
| EPS Diluted | 56.05% | 56.02% | 59.56% | 63.41% | -194.10% |
| Normalized Diluted EPS | -14.02% | -12.64% | 1.06% | 14.48% | 0.38% |
| Average Basic Shares Outstanding | -1.98% | -2.10% | -1.83% | -1.41% | -1.03% |
| Average Diluted Shares Outstanding | -1.98% | -2.10% | -1.83% | -1.41% | -1.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
